SCHEMBL2556469

SCHEMBL2556469

CC(C)CCCC(CCC(C)C)NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.40
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
KIF11 P52732 1/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
HRH1 P35367 3/20 0.33
HTR2A P28223 2/20 0.33
TTR P02766 1/20 0.33
LMNA P02545 1/20 0.32
PKM P14618 1/20 0.32
CYP3A4 P08684 1/20 0.32
CACNA1F O60840 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7317772 0.72 TRPA1 (0.41) KCNN4ALDH1A1KIF11CYP2D6CYP2C19
SCHEMBL7312975 0.72 TRPA1 (0.41) KCNN4ALDH1A1KIF11CYP2D6CYP2C19
SCHEMBL7479981 0.70 KCNN4 (0.43) KCNN4ALDH1A1MEN1KMT2AKIF11
SCHEMBL7486375 0.69 KCNN4 (0.44) KCNN4ALDH1A1KIF11LMNACHRM3
SCHEMBL6566499 0.68 KCNN4 (0.52) KCNN4ALDH1A1MEN1KMT2AHTT
SCHEMBL16609226 0.68 KCNN4 (0.52) KCNN4ALDH1A1MEN1KMT2AHTT
SCHEMBL2490293 0.68 KCNN4 (0.38) KCNN4ALDH1A1MEN1KMT2AKIF11
SCHEMBL3302423 0.68 KCNN4 (0.47) KCNN4ALDH1A1MEN1KMT2AKIF11
SCHEMBL3302429 0.68 KCNN4 (0.47) KCNN4ALDH1A1MEN1KMT2AKIF11
SCHEMBL28513998 0.68 KCNN4 (0.42) KCNN4ALDH1A1MEN1KMT2AKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263607-A1 ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER PRISM BIOLAB CORPORATION (JP) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263607-A1 ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER COL1A1, HDGF, HCCS KCNN4 4850/4885ALDH1A1 1264/4885MEN1 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.